scieee Open visual document viewer

Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease

Klasic, M,Markulin, D,Vojta, A,Samaržija, I,Biruš, I,Dobrinic, P,Ventham, N,Trbojevic-Akmacic, I,Šimurina, M,Štambuk, J,Razdorov, G,Kennedy, N,Satsangi, J,Dias, AM,Pinho, S,Annese, V,Latiano, A,D'Inca, R,Lauc, G,Zoldoš, V

Abstract

The authors would like to thank Stephanie Scott for her organizational and administrational contribution. The study has been funded by the EU FP7 grant European Commission IBD-BIOM (contract # 305479), EU FP7 Regional Potential Grant INTEGRA-Life (contract # 315997), European Structural and Investment Funds grant for the Croatian National Centre of Research Excellence in Personalized Healthcare (contract # KK.01.1.1.01.0010), and Croatian Science Foundation grant EpiGlycoIgG (contract # 3361). Financial support from Portugal (PI: SSP): FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project (POCI-01/0145-FEDER-016601; PTDC/DTP-PIC/0560/2014) was received. SSP also acknowledges the European Crohn’s and Colitis Organization (ECCO) and the “Broad Medical Research program at Crohn’s and Colitis Foundation of America-CCFA” for funding. SSP acknowledges the Portuguese Group of Study on IBD (GEDII) for funding. A.M.D. [PD/BD/105982/2014] also acknowledges FCT for funding. IBD-BIOM consortium: Daniel Kolarich (Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany), Manfred Wuhrer (Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands; Division of BioAnalytical Chemistry, VU University Amsterdam, Amsterdam, the Netherlands), Dermot P. B. McGovern (F. Widjaja Family Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles), Iain K. Pemberton (IP Research Consulting SAS, Paris, France), Daniel IR Spencer (Ludger Ltd., Culham Science Centre, Oxford, UK, Daryl L. Fernandes (Ludger Ltd., Culham Science Centre, Oxford, UK), Rahul Kalla, Kate O’Leary, Alex T Adams, Hazel Drummond, Elaine Nimmo, Ray Boyapati, David C Wilson (Centre for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK), Ray Doran (Ludger Ltd., Culham Science Centre, Oxford, UK), Igor Rudan (all, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK), Paolo Lionetti (Paediatric Gastroenterology Unit, AOU Meyer, Viale Pieraccini, Florence, Italy), Natalia Manetti (Department of Medical and Surgical Sciences, Division of Gastroenterology, University Hospital Careggi, Florence, Italy), Fabrizio Bossa (Department of Medical Sciences, Division of Gastroenterology, IRCCS-CSS Hospital, Viale Cappuccini, Rotondo, Italy), Paola Cantoro, Anna Kohn (Division of Gastroenterology, S. Camillo Hospital, Rome, Italy), Giancarlo Sturniolo (Gastrointestinal Unit, University of Padua, Padua, Italy), Silvio Danese (IBD Unit, Humanitas Research Institute, Rozzano, Milan, Italy), Mariek Pierik (Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands), and David C. Wilson (Centre for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK). This independent research was generously supported by the following grants: EU FP7 research grant IBD-BIOM (contract # 305479) to JS, VA, GL, and VZ; EU FP7 Regional Potential Grant INTEGRA-Life (contract # 315997) to GL and VZ; European Structural and Investment Funds grant for the Croatian National Centre of Research Excellence in Personalized Healthcare (contract # KK.01.1.1.01.0010) to GL and VZ; Croatian Science Foundation grant EpiGlycoIgG (contract # 3361) to VZ; FEDER COMPETE 2020 POCI, Portugal 2020, and Portuguese funds through FCT (contracts # POCI-01/0145-FEDER-016601 and PTDC/DTP-PIC/0560/2014) to SP; and FTC (contract # PD/BD/105982/2014) to AMD.

Full text

RESEARCH Open Access P omo e me hyla ion o he MGAT3 and BACH2 genes co ela es wi h he composi ion o he immunoglobulin G glycome in in lamma o y bowel disease Ma ija Klasić 1† , Do a Ma kulin 1† , Aleksanda Voj a 1 , I ana Sama žija 1 , I an Bi uš 1 , Paula Dob inić 1 , Nicholas T. Ven ham 2 , I ena T boje ić-Akmačić 3 , Mi na Šimu ina 3 , Je ko Š ambuk 3 , Genadij Razdo o 3 , Nicholas A. Kennedy 2,5 , Jack Sa sangi 2,10 , Ana M. Dias 6 , Salome Pinho 6 , Vi o Annese 7 , Anna La iano 8 , Rena a D’Inca 9 , IBD conso ium, Go dan Lauc 3,4 and Vla ka Zoldoš 1* Abs ac Backg ound: Many genome- and epigenome-wide associa ion s udies (GWAS and EWAS) and s udies o p omo e me hyla ion o candida e genes o in lamma o y bowel disease (IBD) ha e demons a ed signi ican associa ions be ween gene ic and epigene ic changes and IBD. Independen GWA s udies ha e iden i ied gene ic a ian s in he BACH2,IL6ST,LAMB1,IKZF1,andMGAT3 loci o be associa ed wi h bo h IBD and immunoglobulin G (IgG) glycosyla ion. Me hods: Using bisul i e py osequencing, we analyzed CpG me hyla ion in p omo e egions o hese i e genes om pe iphe al blood o se e al hund ed IBD pa ien s and heal hy con ols (HCs) om wo independen coho s, espec i ely. Resul s: We ound signi ican di e ences in he me hyla ion le els in he MGAT3 and BACH2 genes be ween bo h C ohn’s disease and ulce a i e coli is when compa ed o HC. The same pa e n o me hyla ion changes was iden i ied o bo h genes in CD19 + B cells isola ed om he whole blood o a subse o he IBD pa ien s. A co ela ion analysis was pe o med be ween he MGAT3 and BACH2 p omo e me hyla ion and indi idual IgG glycans, measu ed in he same indi iduals o he wo la ge coho s. MGAT3 p omo e me hyla ion co ela ed signi ican ly wi h galac osyla ion, sialyla ion, and bisec ing GlcNAc on IgG o he same pa ien s, sugges ing ha ac i i y o he GnT-III enzyme, encoded by his gene, migh be al e ed in IBD. The co ela ions be ween he BACH2 p omo e me hyla ion and IgG glycans we e less ob ious, since BACH2 is no a glycosyl ans e ase and he e o e may a ec IgG glycosyla ion only indi ec ly. Conclusions: Ou esul s sugges ha epigene ic de egula ion o key glycosyla ion genes migh lead o an inc ease in p o-in lamma o y p ope ies o IgG in IBD h ough a dec ease in galac osyla ion and sialyla ion and an inc ease o bisec ing GlcNAc on digalac osyla ed glycan s uc u es. Finally, we showed ha CpG me hyla ion in he p omo e o he MGAT3 gene is al e ed in CD3 + T cells isola ed om in lamed mucosa o pa ien s wi h ulce a i e coli is om a hi d smalle coho , o which biopsies we e a ailable, sugges ing a unc ional ole o his glyco-gene in IBD pa hogenesis. * Co espondence: [email p o ec ed] † Ma ija Klasićand Do a Ma kulin con ibu ed equally o his wo k. 1 Depa men o Biology, Di ision o Molecula Biology, Facul y o Science, Uni e si y o Zag eb, Ho a o ac 102a, 10000 Zag eb, C oa ia Full lis o au ho in o ma ion is a ailable a he end o he a icle © The Au ho (s). 2018 Open Access This a icle is dis ibu ed unde he e ms o he C ea i e Commons A ibu ion 4.0 In e na ional License (h p://c ea i ecommons.o g/licenses/by/4.0/), which pe mi s un es ic ed use, dis ibu ion, and ep oduc ion in any medium, p o ided you gi e app op ia e c edi o he o iginal au ho (s) and he sou ce, p o ide a link o he C ea i e Commons license, and indica e i changes we e made. The C ea i e Commons Public Domain Dedica ion wai e (h p://c ea i ecommons.o g/publicdomain/ze o/1.0/) applies o he da a made a ailable in his a icle, unless o he wise s a ed. Klasiće al. Clinical Epigene ics (2018) 10:75 h ps://doi.o g/10.1186/s13148-018-0507-y Backg ound In lamma o y bowel disease (IBD) is a ch onic in es inal in lamma o y condi ion classi ied in wo majo o ms— C ohn’s disease (CD) and ulce a i e coli is (UC)—which exhibi e iologically and clinically dis inc ea u es. Now- adays, IBD a ec s 2.5–3 million people in Eu ope and causes conside able mo bidi y [1]. Despi e nume ous clinical, gene ic, and o he expe imen al s udies, ou unde s anding o IBD de elopmen and p og ession emains incomple e. I is gene ally accep ed ha IBD ep esen s an abe - an immune esponse o gu mic obio a in gene ically suscep ible indi iduals [2]. Genome-wide associa ion s udies (GWAS) ha e iden i ied o e 200 gene ic suscep- ibili y loci, he majo i y o which we e associa ed wi h bo h o ms o IBD in genome-wide me a-analysis [3–7]. Howe e , common gene ic a ian s accoun only o 8.2 and 13.1% he i abili y o UC and CD, espec i ely [7]. In e ac iono anindi idual’s gu mic obiome, im- mune sys em, gene ic backg ound, and en i onmen al ac o s, such as smoking, die , d ugs, and physical ac i i y [2,8–10], makes IBD a complex e iopa ho- genic en i y. The challenge is he e o e o iden i y addi ional ac o s in ol ed in he de elopmen and p og ession o his disease, especially gi en i s apidly inc easing incidence. I is p obable ha epigene ics play a key ole in he in e ac ions be ween en i on- men al, mic obial, and gene ic ac o s ha pa icipa e in IBD de elopmen and p og ession. These include DNA me hyla ion and his one modi ica ions, as well as some o he epigene ic mechanisms [11–13]; o a e iew, see [14,15]. DNA me hyla ion emains he mos s udied epigene ic modi ica ion, eadily assayed in a la ge numbe o indi- iduals/samples. Hype me hyla ion o gene p omo e s is gene ally associa ed wi h gene silencing, while p omo e hypome hyla ion is associa ed wi h gene ac i a ion [16]. En i onmen ally changed DNA me hyla ion pa e n may con ibu e o he de elopmen o many complex diseases by media ing he in e play be ween ex e nal and in e nal ac o s and he gene exp ession [17–21]. The e a e also da a o sugges ha he a o emen ioned en i onmen- al modi ie s o IBD can also a ec DNA me hyla ion [17–19,22]. Epigene ic componen o IBD has been add essed in many s udies, mos ly by whole genome me hyla ion analysis pe o med on pe iphe al blood mononuclea cells (PBMCs) o mucosal issue, e eal- ing egions di e en ially me hyla ed be ween he diseaseandheal hys a e,aswellasbe weenCDand UC [11–13,23–26]. The majo i y o euka yo ic p o eins a e modi ied by addi ion o complex oligosaccha ides (glycans) h ough he p ocess o glycosyla ion. The e o e, glycans a e an in eg al pa o nea ly all memb ane and sec e ed p o eins, including componen s o he immune sys em [27]. Abe an p o ein glycosyla ion is implica ed in i ually e e y human complex disease, including in lam- ma ion [28–31]. P e ious s udies ha e sugges ed ha N-glycosyla ion o sec e ed and memb ane p o eins migh be egula ed epigene ically and ha abe an gly- cosyla ion p o iles in disease can a ise h ough abe an epigene ics [32–38]. A comp ehensi e e iew abou he ole o p o ein glycosyla ion in IBD has been gi en ecen ly [39]. N-glycosyla ion o se um-ci cula ing p o- eins (such as he acu e phase p o eins; immunoglobulin G, IgG; and immunoglobulin A, IgA) o whole plasma N-glycome (i.e., N-glycans p esen on all plasma p o- eins) has been he ocus o IBD bioma ke disco e y [36,40–43]. In addi ion, ou pa ne s om IBD conso - ium and o he s es ablished ha al e ed glycosyla ion o IgG, which is a key e ec o o he humo al immune sys em, has a ole in balancing in lamma ion a he sys- emic le el [42–46]. GWA s udies indica ed associa ions o IBD wi h se - e al loci in ol ed in p o ein glycosyla ion [47,48]. Mo e ecen ly, he i s GWAS o IgG glycosyla ion iden i ied 16 loci speci ically associa ed wi h changes in IgG glyco- syla ion [49]. In e es ingly, i e o hese loci showed plei- o opy wi h IBD: MGAT3, a glyco-gene encoding o a glycosyl ans e ase, GnT-III; LAMB1, a membe o ansmemb ane glycop o ein amily o ex acellula ma ix; he IL6ST, a signal ansduce sha ed by many cy okines; IKZF1; and BACH2, ansc ip ion ac o s in- ol ed in B cell di e en ia ion, ac i a ion, and ma u - a ion. Only he MGAT3 is a classical glyco-gene wi h a known unc ion in IgG glycosyla ion, while he exac unc ional oles o o he ou GWAS hi s in IgG glyco- syla ion o IBD emain unknown. In his s udy, we in es iga ed p omo e me hyla ion di e ences in hese i e genes, associa ed wi h bo h IBD and IgG glycosyla ion, in pe iphe al whole blood o se e al hund ed IBD pa ien s om wo independen coho s. We also co ela ed p omo e me hyla ion da a wi h IgG glycosyla ion da a analyzed p e iously o he same IBD pa ien s by ou pa ne s om he IBD conso - ium [43,46,50]. Pe iphe al blood was used o DNA me hyla ion analysis and se um o plasma was used o glycan analysis, since one o ou goals was he sea ch o po en ial IBD bioma ke s. As pe iphe al whole blood is a he e ogeneous cell mix u e wi h speci ic me hyla ion pa e n o each o he cell ypes [51], we also analyzed p omo e me hyla ion o ou candida e genes in CD19 + B cells and CD3 + T cells isola ed om pe iphe al blood mononuclea cells (PBMCs). B cells we e o ou pa icu- la in e es since hese cells p oduce IgG on hei mem- b ane and a e p ecu so s o plasma cells which sec e e IgG. We ha e u he explo ed i abe an p omo e me hyla ion eco ded in pe iphe al whole blood o IBD Klasiće al. Clinical Epigene ics (2018) 10:75 Page 2 o 14 pa ien s can be a p oxy o epigene ic e en s occu ing in he in lamed mucosa. To add ess his ques ion, we analyzed DNA me hyla ion om PBMCs, CD3 + T cells isola ed om PBMCs, and CD3 + T cells isola ed om in lamed colonic mucosa o UC pa ien s om he hi d smalle coho , o which biopsies we e a ailable. Me hods Pa ien selec ion and e hics Pa ien s we e ec ui ed p ospec i ely om Edinbu gh, UK, and Flo ence, I aly, as a pa o he IBD-BIOM p o- jec . The ec ui men o pa ien s om Edinbu gh has been desc ibed elsewhe e [13,43]. B ie ly, we ec ui ed IBD pa ien s p ospec i ely as close as possible o he da e o diagnosis om gas oen e ology ou pa ien and endoscopy appoin men s be ween 2012 and 2015. We ec ui ed symp oma ic con ols om gas oen e ology clinics du - ing he same pe iod. In hese indi iduals, we had excluded IBD and o he o ganic bowel pa hology ollowing bio- chemical and/o endoscopic in es iga ions. We ec ui ed a u he heal hy olun ee coho wi h no gas oin es inal symp oms. IBD pa ien s we e s a i ied by disease ype (ulce a i e coli is, UC, and C ohn’s disease, CD). De ailed gene ic, pheno ypic, and o he da a ega ding IBD cases a e gi en in Addi ional ile 1: Tables S1 and S2. Flo ence coho was collec ed h ough he ne wo k o he I alian G oup o IBD (IG-IBD) since he beginning o 2001 and i s desc ibed in 2005 [1] ollowing an in e nal alida ion o pheno yping. Subsequen ly, longi udinal upda e has been pe o med on a yea ly basis. E hical app o als we e ob ained om Tayside Com- mi ee on Medical E hics B, and all pa ien s and con ols p o ided w i en, in o med consen (LREC 06/S1101/16, LREC 2000/4/192). Flo ence ec ui men de ails IBD pa ien s we e p ospec i ely ec ui ed as close as possible o he da e o diagnosis om gas oen e ology ou pa ien and endoscopy appoin men s be ween yea s 2012 and 2015 in di e en e ia y e e al cen e s in San Gio anni Ro ondo, Rome, Rozzano (Milan), Padua, and Flo ence, I aly. Symp oma ic con ols we e ec ui ed in he same cen e s (gas oen e ology clinics) du ing he same pe iod. In hese indi iduals, IBD and o he o ganic bowel pa hology we e excluded by biochemical and/o endoscopic in es iga ions. IBD pa ien s we e s a i ied by disease ype (ulce a i e coli is, UC, and C ohn’s disease, CD). Samples we e ob ained wi h he same me hodology (see u he ) and cen ally collec ed a San Gio anni Ro ondo, I aly. Sample collec ion We collec ed whole blood a he ime o pa ien ec ui - men in o 9-ml se um Z-clo ac i a o ubes (G eine ), allowed hem o clo a 4 °C o 60 min, and hen cen i- uged a 2500×g o 15 min. The se um was aliquo ed o and s o ed a −80 °C un il u he analysis. A subse o pa ien s and con ols ec ui ed in Edinbu gh (Addi ional ile 1: Table S3) unde wen immunomagne ic cell sepa a ion o ob ain CD19 + B cells. The me hods ha e p e iously been de ailed elsewhe e [13]. Venepunc u e using 9-ml K3 EDTA acue e (G eine ) ubes was pe o med o ob ain be ween o 18 and 36 ml o EDTA-bu e ed blood. An ini ial Ficoll (Ficoll-Paque, GE Heal hca e, Bucks, UK) densi y g adien cen i uga ion was pe o med o ob ain pe iphe al blood mononuclea cells. Cells labelled wi h an ibody-coa ed mic obeads (human CD8 + and CD19 + mic obeads, 20 μlpe 1×10 7 cells) we e immunomagne ic sepa a ed using he au o- MACs P o cell sepa a o (Mil enyi, Ge many). CD19 + sepa a ions we e pe o med ollowing an ini ial CD8 + deple ion s ep. Nucleic acids we e ex ac ed using AllP ep (Qiagen, Hilden, Ge many) acco ding o he manu ac- u e ’s guidance and s o ed a −80 °C. Colonic biopsies om con ols and UC pa ien s wi h inac i e and ac i e o m o disease we e mechanically dissocia ed o p epa e single-cell suspensions using Hanks’balanced sal solu ion modi ied medium, wi hou calcium chlo ide and magnesium sul a e (HBSS) (Sigma), wi h penicillin/s ep omycin and gen amicin. PBMCs we e ob ained by densi y g adien cen i uga ion using Lymphop ep. CD3 + T cells ( om biopsies and blood) we e magne ically so ed by using he EasySep™Human T Cell En ichmen Ki (STEMCELL) ollowing he man- u ac u e ’s ins uc ions. Following cell isola ion, DNA ex ac ion was pe o med using he In iso b Spin Tissue Mini Ki (S a ec Molecula ) ollowing he manu ac- u e ’s ins uc ions. DNA me hyla ion analysis We analyzed p omo e me hyla ion o he candida e genes in he DNA om whole blood, as well as om he sepa a ed CD19 + B cells. In addi ion, o he MGAT3, which is a glycosyl ans e ase wi h di ec and known unc ion in IgG glycosyla ion [52], we analyzed p omo e me hyla ion—in DNA om PBMCs, CD3 + T cells iso- la ed om PBMCs, and CD3 + T cells isola ed om he colonic mucosa o heal hy con ols and UC pa ien s (classi ied acco ding o ac i e and inac i e o m o he disease) o he hi d independen smalle subcoho col- lec ed by he Gas oen e ology Depa men o Cen o Hospi ala do Po o-Hospi al de San o An ónio, Po ugal (Addi ional ile 1: Table S4). All specimens we e sub- jec ed o his ological examina ion and classi ica ion. All pa icipan s ga e in o med consen abou all clinical p ocedu es, and esea ch p o ocols we e app o ed by he e hics commi ee o CHP/HSA, Po ugal (233/ 12(179-DEFI/177-CES). Klasiće al. Clinical Epigene ics (2018) 10:75 Page 3 o 14 Fo DNA me hyla ion analysis, 500 ng o DNA om whole blood was bisul i e con e ed using EZ-96 DNA Me hyla ion Gold ki (Zymo Resea ch, F eibu g, Ge many), and 100 ng o DNA om CD19 + B cells, PBMCs, and T cells was con e ed using EZ DNA Me hyla ion Gold ki (Zymo Resea ch, F eibu g, Ge many) acco ding o he manu ac u e ’s p o ocol. Two o six py osequencing assays we e de eloped o p omo e egions o each o he i e candida e genes (BACH2,MGAT3,IL6ST,IKZF1, and LAMB1). The se- lec ion o analyzed CpG si es was andom o assays 2–5 o he MGAT3 gene. CpG si es wi hin he MGAT3 assay 1 we e selec ed based on he GEO (Gene Exp ession Omnibus) da abase whe e me hyla ion da a we e ob ained using Illumina HumanMe hyla ion450 Bead- Chip 1.1 echnology. Fo he BACH2 gene, assays we e selec ed based on loca ion o di e en ially me hyla ed CpGs in di e en cell lines es ed by ENCODE p ojec , using Illumina HumanMe hyla ion450 BeadChip 1.1 echnology (a newe e sion, he In inium Me hyla ionE- PIC 850K was no a ailable a he ime). We used adi ional bisul i e-based p o ocols which canno disc imina e be ween 5-me hylcy osine (5-mC) and 5-hyd oxyme hylcy osine (5-hmC) as oxida i e bisul i e (oxBS-450K) me hod can [53]. Howe e , ecen s udies ha e shown ha global DNA hyd oxyme hyla ion is e y low in blood cells [54,55]. Fu he mo e, hyd oxyme hy- la ion is signi ican ly deple ed om p omo o s and CpG islands, while en iched in he gene bodies [53,56]. Based on he es ima ed s a is ical powe , we did ini ial sc eening on 60 pa ien s o each py osequencing assay, a e which we excluded hose genes (py osequencing assays) ha did no show any s a is ically signi ican di - e ences be ween IBD pa ien s and heal hy con ols. Py osequencing assays o LAMB1,IL6ST, and IKZF1 a e shown in Addi ional ile 2: Figu e S1. We con inued o analyze p omo e me hyla ion only in he BACH2 and MGAT3 genes. Speci ic egions we e ampli ied using Py oMa k PCR ki (Qiagen, Hilden, Ge many). The cyc- ling condi ions o he BACH2 gene we e as ollows: ini- ial polyme ase ac i a ion s ep o 15 min a 95 °C ollowed by 50 cycles o 30 s dena u a ion a 95 °C, p i- me annealing o 30 s a p ime -speci ic empe a u es (Addi ional ile 1: Table S5), and 30 s a 72 °C, wi h inal ex ension a 72 °C o 10 min. The cycling p o ocol used o ampli ica ion o he MGAT3 gene agmen s was de- sc ibed p e iously [35], wi h he annealing empe a u e adjus ed o 55 °C o he agmen 1 pe o med on DNA om CD19 + B cells. Fo quan i a i e measu emen o DNA me hyla ion le el a speci ic CpG si es, PCR-ampli ied bisul i e-con e ed DNA was sequenced using he Py oMa k Q24 Ad anced py osequencing sys- em (Qiagen) acco ding o he manu ac u e ’s ecom- menda ions. Sequences o PCR and py osequencing p ime s o he BACH2 and he MGAT3 genes a e lis ed in Addi ional ile 1: Table S5. EpiTec PCR Con ol DNA Se (me hyla ed and unme hyla ed bisul i e-con e ed human DNA, Qiagen) was used as a con ol o PCR and py osequencing eac ions. S a is ical analysis The nonpa ame ic Mann-Whi ney U es was used o compa e he me hyla ion s a us o CpG si es encom- passed by he py osequencing assays in he MGAT3 and BACH2 genes be ween he wo independen g oups: HC compa ed o each o CD o UC. Signi icance h eshold was se a p< 0.05 wi h addi ional Bon e oni co ec ion o mul iple es ing. Gi en ha age was ou p ima y conce n as a po en ial con ounde , we isualized he age in he h ee g oups (CD, UC, and HC) o he samples included in each analysis as iolin plo s (Addi ional ile 3: Figu e S2) and assu ed he e was no signi ican di e - ence be ween he age g oups (p> 0.05) using he Mann-Whi ney U es . This was done o assu e he alidi y and s eng hen he a ionale o he selec ion o s a is ical me hods. Fo heda ao heMGAT3 p omo e me hyla ion om PBMCs, CD3 + T cells isola ed om blood, and CD3 + T cells isola ed om in lamed colonic mucosa ( he Po o coho ), he Mann-Whi ney U es was applied wi h Bon e oni co ec ion accoun ing o 15 CpG si es. Glycan analysis Glycans p esen on IgG we e analyzed om se um o o e 1000 IBD (UC and CD) pa ien s and heal hy con- ols in he Edinbu gh coho using ul a pe o mance liquid ch oma og aphy (UPLC) [43,50]. In he Flo ence coho , plasma samples o 3500 IBD pa ien s and heal hy con ols was used o analysis o IgG glycopep ides by liquid ch oma og aphy coupled o mass spec ome y (LC-MS) [46]. The da a o IgG glycosyla ion analysis we e used in his wo k o co ela ion analysis wi h p o- mo e me hyla ion da a o MGAT3 and BACH2 genes, wi h ma ching samples om he e y same pa ien s and heal hy con ols. Isola ion o IgG om blood plasma IgG has been isola ed om blood plasma by a ini y ch oma og aphy using CIM P o ein G 96-well pla e (BIA Sepa a ions, Ajdo ščina, Slo enia) and acuum mani old (Pall Co po a ion, Po Washing on, NY, USA) as p e iously desc ibed [57,58]. In sho , plasma sam- ples (50–90 μl) we e dilu ed wi h 1 × PBS, pH 7.4 in he a io 1:7. All samples we e il e ed h ough 0.45 and 0.2-μm Ac oP ep GHP il e pla es (Pall Co po a ion) using acuum mani old and immedia ely applied o p e- condi ioned P o ein G pla e. A e washing o he Klasiće al. Clinical Epigene ics (2018) 10:75 Page 4 o 14 P o ein G pla e, IgG was elu ed wi h 0.1 mol L −1 o mic acid and immedia ely neu alized wi h ammonium bica - bona e o pH 7.0. P o ein G pla e was egene a ed and s o ed a 4 °C. IgG glycosyla ion analysis using ul a-pe o mance liquid ch oma og aphy N-glycans om isola ed IgG in he Edinbu gh coho we e eleased wi h PNGase F a e d ying 300 μl o each IgG elu ion ac ion, labeled wi h 2-aminobenzamide and excess o egen s emo ed by clean-up using hyd o- philic in e ac ion liquid ch oma og aphy solid phase ex ac ion (HILIC-SPE). Fluo escen ly labeled and pu i- ied N-glycans we e sepa a ed by HILIC-UPLC using Acqui y UPLC ins umen (Wa e s, Mil o d, MA, USA) as p e iously desc ibed [43]. Samples we e sepa a ed in o 24 peaks [57], and he amoun o N-glycans in each ch oma og aphic peak was exp essed as a pe cen age o o al in eg a ed a ea (% a ea). IgG glycosyla ion analysis using liquid ch oma og aphy coupled o mass spec ome y In he Flo ence coho , Fc-speci ic IgG glycopep ides we e analyzed a e IgG pu i ica ion, o e nigh ypsin diges ion a 37 °C, and e e se-phase pu i ica ion on Ch omabond C18 beads using acuum mani old as desc ibed [46,59]. Samples we e analyzed using nanoli- quid ch oma og aphy coupled o mass spec ome y (nanoLC-MS), on a nanoACQUITY UPLC sys em (Wa e s, Mil o d Massachuse s, USA) coupled o quad upole-TOF-MS (Compac ; B uke Dal onics, B emen, Ge many) equipped wi h a shea h- low ESI sp aye (capilla y elec opho esis ESI-MS sp aye ; Agilen Technologies, San a Cla a, USA) as p e iously desc ibed [46]. The nanoACQUITY UPLC sys em and he B uke Compac Q-TOF-MS we e ope a ed unde HyS a so wa e e sion 3.2. Da a was p ocessed as desc ibed p e iously [46,60]. This esul ed in he ex ac ion o 16 IgG1, 16 IgG2/3, and 11 IgG4 glyco o ms. The yp ic Fc-glycopep ides o IgG2 and IgG3 subclasses ha e iden ical pep ide moie ies in he Caucasian popula ion and a e he e o e no dis inguishable wi h his me hodology. Anno a ion o he spec a was done based on accu a e mass acco d- ing o he ele an li e a u e [40,57]. Co ela ion analysis Me hyla ion da a o he BACH2 (assay 2) and he MGAT3 (assays 1 and 2) genes (ob ained o he wo la ge coho s) we e il e ed acco ding o he peak quali y by ejec ing peaks ma ked as “ ailed”by he py ose- quencing so wa e. A e age me hyla ion ac oss all assayed CpG si es was calcula ed o each py osequenc- ing assay in each coho . Me hyla ion esul s o indi idual pa ien s we e ma ched wi h hei co espond- ing glycan p o iles. Sizes o da ase s and pa ien classes ob ained a e including comple e eco ds (i.e., bo h me hyla ion da a and glycan p o iles p esen ) a e shown in Addi ional ile 1: Table S6. Indi idual glycan s uc- u es we e ep esen ed as ela i e abundances and ba ch-co ec ed. Pe cen age o s uc u es wi h bisec ing N-ace ylglucosamine was calcula ed o each coho as a de i ed ai a his poin . Glycan s uc u es iden i ied by each me hod we e ansla ed o Ox o d no a ion, and only he 13 s uc u es p esen in bo h he Edinbu gh and Flo ence da ase s we e conside ed o co ela ion. We used IgG1 da a om he Flo ence coho , as his iso o m was he mos abundan . Th ee addi ional de- i ed ai s we e calcula ed: a ios o FA2B o FA2, FA2BG1 o FA2G1, and FA2BG2 o FA2G2. Pea son co ela ion be ween CpG me hyla ion da a and 17 glycan ea u es (13 s uc u es and 4 de i ed ai s) was calcula ed. Signi icance h eshold was se a p< 0.05 wi h addi ional Bon e oni co ec ion o 17- old mul iple es ing. Me hyla ion o assayed CpG si es in p omo e s o he BACH2 and MGAT3 genes was co ela ed wi h mea- su ed glycan s uc u es. Pea son co ela ion coe icien along wi h he associa ed p alue was calcula ed be ween a e age CpG me hyla ion ( o all genes/assays) and each measu ed IgG glycan s uc u e. Calcula ion was done on pai wise comple e obse a ions. Only co ela ions wi h he p alue below 0.01 we e conside ed u he . Nex , co ela ion coe icien s o all CpG assays we e calcu- la ed, which was used o ank glycan s uc u es acco d- ing o egula ion by he assayed egion. Glycan s uc u es wi h he s onges co ela ion (ei he posi i e o nega i e) o CpG me hyla ion we e hen used o explain egula o y e ec s. All calcula ions and da a isu- aliza ions we e done in R language and en i onmen o s a is ical compu ing (R Founda ion o S a is ical Com- pu ing, Vienna, Aus ia). Visualiza ion o co ela ions was done using he R package “co plo .” Resul s P omo e me hyla ion o he candida e genes in whole blood and B cells o IBD pa ien s In o de o assess he le el o me hyla ion in CpG islands o he i e candida e genes (BACH2,MGAT3, IKZF1,LAMB1,andIL6ST), associa ed wi h bo h IBD and IgG glycosyla ion by GWAS, we de eloped se - e al py osequencing assays o each o he genes (Fig. 1and Addi ional ile 2:Figu eS1).Wepe - o med ini ial sc eening o he py osequencing assays on 60 pa ien s. O e all cy osine me hyla ion le els we e e y low o LAMB1 (a e age alue pe g oup < 8%), o IL6ST (< 3.5%), and o IKZF1 (< 4%) in he assayed po ion o hei p omo e s; he e o e, we Klasiće al. Clinical Epigene ics (2018) 10:75 Page 5 o 14 could no iden i y di e en ial me hyla ion. We hen excluded hese genes om u he analysis. MGAT3 and BACH2 p omo e me hyla ion was ana- lyzed in se e al hund ed IBD pa ien s and heal hy con- ols om wo independen coho s (Addi ional ile 1: Tables S1 and S2). In hese genes, we analyzed me hyla- ion le el a 47 CpGs co e ed by i e py osequencing as- says in he BACH2 gene: 21 CpG si es we e in he p omo e egion, 1 CpG si e was in i s exon, and 25 CpG si es we e loca ed in he i s in on o he gene. A o al o 32 CpG si es, co e ed by i e py osequencing assays, was analyzed o MGAT3: 18 CpG si es we e loca ed in he p omo e egion and 14 CpG si es in he i s in on (Fig. 1). Mos o hose CpG si es we e loca ed wi hin CpG islands o he bo h genes. We ound di e en ial CpG me hyla ion be ween IBD pa ien s and HC wi hin he assay A2, loca ed a 213–368 bp up- s eam ( ela i e o he gene o ien a ion) o he TSS in he BACH2 p omo e and wi hin he assays A1 and A2, loca ed in he CpG island 1 o he MGAT3 gene. The same pa e n o di e en ial me hyla ion a hese CpG si es was obse ed in whole blood o pa ien s and HC om wo la ge independen coho s (Fig. 2). CpG me hyla ion le el was gene ally low (up o 20%) in he assayed po ion o he BACH2 p omo e ; howe e , sig- ni ican di e ences be ween HC and CD me hyla ion le el we e eco ded a CpG si es 4, 5, 6, and 8 (Fig. 2a). Fo he assayed po ion o he MGAT3 p omo e , gene al me hyla ion le el was high, wi h all CpG si es show- ing a ep oducibly signi ican di e ence be ween HC andbo hCDandUC.CpGsi es2,13,and15 showed signi ican di e ences only o CD bu no o UC. Di ec ion o change was di e en o he wo genes—di e en ially me hyla ed CpG si es wi hin he BACH2 p omo e we e hypome hyla ed, while hose o he MGAT3 gene we e hype me hyla ed in disease compa ed o heal hy indi iduals. These esul s we e con i med on CD19 + Bcells isola ed om pe iphe al whole blood o he independ- en , smalle pa ien sample om he Edinbu gh coho (67 samples). The CpG si es 1–5 and 12–13 in he MGAT3 p omo e we e di e en ially me hyla ed be ween CD and HC. Only CpG si e 5 wi hin he assay A2 o he BACH2 gene showed change in he me hyla ion le el be ween HC and CD in CD19 + B cells (Fig. 2b). The e we e no di e ences in he me hyla ion le el o he same CpG si es wi hin assayed agmen s o he BACH2 and MGAT3 genes be ween UC and HC. I is wo h no ing ha he same pa e n o CpG me hyla ion di e ences was obse ed in PBMCs o he IBD pa ien s and HC om bo h la ge independen coho s, and mos o he CpG si es wi hin he assayed po ion o he MGAT3 p omo e we e also di e en ially me hyla ed in CD19 + B cells om he subse o IBD pa ien s om he Edinbu gh coho (Fig. 2a,b). Fig. 1 Posi ions o he BACH2 and MGAT3 genes in he human genome and ela i e posi ions o he agmen s analyzed o me hyla ion le el (py osequencing assays) wi hin hese genes. Fo each py osequencing assay (A1–A5), he egion ampli ied by PCR is shown. Posi ions o he genes on he ch omosomes a e shown using ch omosome models ( ed e ical lines). Coo dina es a e ela i e o he hg19 human genome assembly. The genes a e displayed in he di ec ion co esponding o hei eading ames. Anno a ions (CpG islands and py osequencing assays) a e o scale. TSS ansc ip ion s a si e Klasiće al. Clinical Epigene ics (2018) 10:75 Page 6 o 14 a b Fig. 2 (See legend on nex page.) Klasiće al. Clinical Epigene ics (2018) 10:75 Page 7 o 14 P omo e me hyla ion o he MGAT3 gene in CD3 + T cells om PBMCs and in lamed colonic mucosa o UC pa ien s We included in ou in es iga ion biopsy samples o UC pa ien s om an independen coho om he Gas o- en e ology Depa men o Cen o Hospi ala do Po o-Hospi al de San o An ónio, Po ugal. Gi en he echnical challenges in ob aining DNA and RNA om a small numbe o pu i ied cells om in lamed colonic mucosa, a subse o pa ien s wi h ac i e and inac i e phase o UC was selec ed o me hyla ion analysis om h ee sou ces: (1) PBMCs, (2) CD3 + T cells isola ed om PBMCs, and (3) CD3 + T cells isola ed om colonic mucosa (see also Addi ional ile 1: Table S4). In e -indi idual a ia ion o MGAT3 me hyla ion le el measu ed om PBMCs and om CD3 + T cells isola ed om PBMCs was qui e la ge—i a ied om 47 o 94% and om 26 o 90%, espec i ely. The e o e, we could no ind any di e ence in CpG me hyla ion le el be ween UC pa ien s and HC in assayed agmen s o he MGAT3 p omo e , nei he in PBMCs no in CD3 + T cells isola ed om PBMCs. Howe e , we eco ded a o al o 7 (ou o 15) di e en ially me hyla ed CpG si es in CD3 + T cells isola ed om colonic mucosa o UC pa ien s wi h ac i e disease compa ed wi h HC (Fig. 3). O e all, he me hyla ion le el o CpGs wi hin assayed agmen s o he MGAT3 p omo e was high in CD3 + T cells om heal hy colonic mucosa (be ween 77 and 98%). When compa ed o in lamed mucosa o UC pa ien s wi h ac i e phase o he disease, he same CpG si es we e hypome hyla ed, wi h he highes di e ence a he CpG posi ion 10 (13.24%; p= 5.08 × 10 −5 ; Fig. 3). In inac i e UC, no signi ican di e ences could be ound a e Bon e oni co ec ion o mul iple es ing. I is wo h no ing ha he me hyla ion pa e n in CD3 + T cells isola ed om in lamed colonic mucosa di - e ed om he me hyla ion pa e ns in PBMCs and o CD3 + T cells isola ed om PBMCs. The la e wo we e e y simila and had much lowe me hyla ion le els han ha measu ed o CD3 + T cells om in lamed colonic mucosa (Fig. 3). Also, MGAT3 me hyla ion le el was inc eased in UC compa ed wi h HC when measu ed om PBMCs o CD3 + T cells isola ed om PBMCs (hype me hyla ion), while i was dec eased (hypome hy- la ion) when measu ed om CD3 + T cells isola ed om in lamed colonic mucosa in compa ison wi h heal hy mucosa. Co ela ion be ween he MGAT3 and BACH2 p omo e me hyla ion and IgG glycosyla ion The e we e s a is ically signi ican co ela ions ha epli- ca ed ac oss assays and coho s be ween he MGAT3 p omo e me hyla ion and glycan s uc u es FA2, FA2G2, FA2BG2, and FA2G2S1, as well as he de i ed ai o he a io o FA2B o FA2 (Fig. 4a). All co ela- ions excep wi h FA2 we e nega i e. No ep oducible signi ican co ela ions could be ound be ween BACH2 p omo e me hyla ion and he glycan s uc u es (Fig. 4a). In o de o in e a mechanis ic pa hway o he obse ed co ela ions, we mapped hem o he glycan biosyn hesis pa hways (Fig. 4b). The a io o bisec ing glycans o FA2 was aken as an indica o o MGAT3 (GnT-III) ac i i y. This in e p e a ion allowed us o in e lowe GnT-III enzyma ic ac i i y when he p omo e o he MGAT3 gene was me hyla ed. Inc ease in MGAT3 p omo e me hyla ion co ela ed wi h a dec ease in ce - ain galac osyla ed and sialyla ed s uc u es (Fig. 4b). In addi ion o he dec eased le els o bisec ing GlcNAc on non-galac osyla ed glycans (B/FA2), he mos signi ican e ec o he MGAT3 p omo e me hyla ion on IgG gly- come composi ion was a dec ease o IgG galac osyla ion. Discussion Resul s om his s udy s ongly indica e ha he MGAT3 and BACH2 genes play an impo an ole in IBD pa hogenesis and sugges a possible disease pa hway media ed by he p o-in lamma o y p ope ies o IgG an ibodies acqui ed by al e a ions in Fc glycosyla ion. Ou ecen s udy, pe o med on a la ge coho o o e 1000 IBD pa ien s, epo ed a signi ican di e ence in IgG glycome composi ion in bo h UC and CD compa ed o heal hy con ols [43,46]. We ound a dec ease in quan i y o galacosyla ed glycans in bo h CD and UC, as well as a dec ease in sialyla ed glycans and an inc ease o bisec ing GlcNAc on digalac osyla ed glycan s uc- u es on IgG in CD. Indeed, al e na i e N-glycosyla ion o an IgG molecule in luences i s unc ion—p o-in lam- ma o y and an i-in lamma o y ac i i y depends on he (See igu e on p e ious page.) Fig. 2 Box plo o CpG me hyla ion in pe iphe al whole blood o he BACH2 and MGAT3 genes in he Edinbu gh and Flo ence coho s and in B cells om a subse o pa ien s om Edinbu gh coho . G oups we e compa ed using he Mann-Whi ney U es wi h signi icance h eshold o p= 0.05, co ec ed o mul iple es ing using he Bon e oni me hod. aMe hyla ion le els we e gene ally low in he assayed po ion o he BACH2 gene p omo e , wi h signi ican di e ences be ween HC and CD me hyla ion a CpG si es 4, 5, 6, and 8 ( eplica ed in bo h coho s). Fo he MGAT3 gene, gene al me hyla ion le el was high, wi h all CpG si es showing a ep oducibly signi ican di e ence be ween HC and bo h CD and UC, excep o CpG si es 2, 13, and 15 o which ep oducible signi ican di e ences we e ound only be ween HC and CD. bIn B cells, isola ed om PBMCs o a subse o he pa ien s om he Edinbu g coho , di e en ial me hyla ion was ound a he CpG posi ion 5 o he BACH2 gene (assay 2) be ween HC and CD, while o he MGAT3 gene, di e en ially me hyla ed we e CpG si es 1–5, 12, and 13 be ween HC and CD. CD C ohn’s disease, UC ulce a i e coli is, HC heal hy con ols Klasiće al. Clinical Epigene ics (2018) 10:75 Page 8 o 14 glycans added on he Cy2 domain o i s Fc egion [29]. These glycans a e o a bian enna y complex ype wi h o wi hou bisec ing GlcNAc, co e ucose, galac ose, and sialic acid esidues [61]. Recen ly, his was con i med in a la ge mul i-cen ic s udy o IgG glycome in IBD [46]. The e o e, glycan changes obse ed on IgG in pe iphe al blood o UC and CD pa ien s a e ob iously associa ed wi h inc eased in lamma o y po en ial o IgG, sugges ing unc ional ele ance o IgG glycosyla ion o IBD. He e, we p opose a possible mechanism unde lying he abe an IgG glycosyla ion pa e n obse ed in IBD [43,46]. Ou o i e candida e genes analyzed in his wo k, he MGAT3, a glycosyl ans e ase which pa ici- pa es in syn hesis o IgG glycans, and he BACH2,a ansc ip ion ac o and a mas e egula o o a ne wo k o genes ele an o B cell in eg i y [62,63], showed di - e en ial me hyla ion in pe iphe al blood o bo h CD and UC pa ien s when compa ed o heal hy indi iduals. E en hough we iden i ied changes in me hyla ion le el o bo h UC and CD compa ed o HC, he di e ences we e mo e p onounced o CD. This is conco dan wi h o he s udies ha explo ed ei he whole genome me hy- la ion o p omo e me hyla ion o candida e genes in IBD [11]. The ex en o he change in IgG glycome com- posi ion was also consis en ly highe in CD han UC compa ed o HC [43,46]. The p o ein encoded by he MGAT3 gene (N-ace yl- glucosaminyl ans e ase III, GnT-III) is esponsible o signi ican unc ional al e a ion o glycans on he Fc egion o an IgG an ibody. The GnT-III adds N-ace yl- glucosamine (GlcNAc) on β1,4-linked mannose in he h ee-mannose co e o N-glycans, p oducing bisec ing GlcNAc s uc u es. In he same CD pa ien s, who showed changed MGAT3 p omo e me hyla ion le el in pe iphe al blood cells, a signi ican inc ease in he pe - cen age o bisec ing GlcNAc on glycans o ci cula ing IgG an ibodies was eco ded, oo. The associa ion o he MGAT3 wi h bo h IgG N-glycosyla ion [49] and C ohn’s disease [4,5] sugges s ha N-glycans wi h bisec ing GlcNAc could be in ol ed in CD pa hogenesis h ough unc ional e ec on IgG an ibody. Co ela ions be ween BACH2 and MGAT3 p omo e me hyla ion and glycan s uc u es ha e gi en u he insigh in o he changes o IgG glycosyla ion pa e n me- dia ed by hose wo genes (Fig. 4b). The MGAT3 a b c Fig. 3 Box plo o CpG me hyla ion le el in he MGAT3 gene p omo e (assays A1 and A2) analyzed om PBMCs (a), CD3 + T cells isola ed om PBMCs (b), and CD3 + T cells isola ed om in lamed colonic mucosa (c) om he independen coho o Po o. Changes be ween UC pa ien s wi h ac i e disease and HC we e s a is ically signi ican only in CD3 + T cells isola ed om in lamed colonic mucosa a CpG posi ions 3 and 7–12 (p< 0.05 a e Bon e oni co ec ion o 15 hypo heses). PBMC pe iphe al blood mononuclea cells, UC ulce a i e coli is, HC heal hy con ols Klasiće al. Clinical Epigene ics (2018) 10:75 Page 9 o 14